Nasal and pulmonary delivery of deslorrelin, a peptide drug

American Pharmaceutical Review

Volumn 7, Issue 5, 2004, Pages 130-139

  Sundaram, Sneha ^a   Bontha, Sirisha ^a   Koushik, Kavitha ^b   Kompella, Uday B ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Barr Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ABARELIX; BUSERELIN; BUSERELIN ACETATE; CETRORELIX; DECAPEPTYL SR; DESLORELIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN RECEPTOR; GOSERELIN; LEUPRORELIN; METAL; METALLOPROTEINASE; NAFARELIN ACETATE; NONAPEPTIDE; POLYGLACTIN; TRELSTAR DEPOT; TRIPTORELIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CATTLE; CHEMICAL BOND; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; ENDOMETRIOSIS; ENERGY; EPITHELIUM CELL; FACIAL BONE; HORMONAL REGULATION; HUMAN; IN VITRO STUDY; INFERTILITY; LUNG ALVEOLUS MACROPHAGE; LUTEINIZING HORMONE RELEASE; MONOLAYER CULTURE; NONHUMAN; OVARY FUNCTION; PARTICLE SIZE; PERMEABILITY BARRIER; POROSITY; PROSTATE CANCER; PROTEIN DEGRADATION; RESPIRATORY EPITHELIUM; TIGHT JUNCTION; TUMOR CELL LINE; UTERUS MYOMA; VISCOSITY;

EID: 7944224088     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. D. H. Coy E. J. Coy J. A. Vilchez-Martinez, A. de la Cruz, A. Arimura, and A. V. Schally. Suppression of gonadotropin release and ovulation in animals by inhibitory analogs of luteinizing hormone-releasing hormone. Curr Top Mol Endocrinol 3: 339-54 (1976).
2. D. H. Coy, F. Labrie, M. Savary, E. J. Coy and A. V. Schally. Antagonistic activity of analogs of luteinizing hormone-releasing hormone (LH-RH) in vitro. Mol Cell Endocrinol 5: 201-8 (1976).
3. M. J. Karten, J. E. Rivier. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev 7: 44-66 (1986).
4. A. V. Schally. LH-RH analogues: I. Their impact on reproductive medicine. Gynecol Endocrinol 13: 401-9 (1999).
5. R. W. Carlson. Sequencing of endocrine therapies in breast cancer - integration of recent data. Breast Cancer Res Treat 75 Suppl 1: S27-32; discussion S33-5 (2002).
6. G. C. Wood, C. Dass, M. R. Iyer, A. M. Fleischner, and B. B. Sheth. Stability of deslorelin injection. PDA J Pharm Sci Technol 51: 176-80 (1997).
7. D. Lacoste, B. Candas, M. Normand, and F. Labrie. Model of the distribution and metabolism of a GnRH superagonist in dogs. Am J Physiol 258: E468-75 (1990).
8. R. U. Agu, H. Vu Dang, M. Jorissen, T. Willems, R. Kinget, and N. Verbeke. Nasal absorption enhancement strategies for therapeutic peptides: an in vitro study using cultured human nasal epithelium. Int J Pharm 237: 179-91 (2002).
9. K. Corkery. Inhalable drugs for systemic therapy. Respir Care 45: 831-5 (2000).
10. M. D. Donovan, G. L. Flynn, and G. L. Amidon. The molecular weight dependence of nasal absorption: the effect of absorption enhancers. Pharm Res 7: 808-15 (1990).
11. A. Lemay, A. E. Metha, G. Tolis, N. Faure, F. Labrie, and A. T. Fazekas. Gonadotropins and estradiol responses to single intranasal or subcutaneous administration of a luteinizing hormone-releasing hormone agonist in the early follicular phase. Fertil Steril 39: 668-73 (1983
12. M. D. Chaplin. Bioavailability of nafarelin in healthy volunteers. Am J Obstet Gynecol 166: 762-5 (1992).
13. U. B. Kompella, B. A. Dani, D. V. Spicer and J. R. Daniels. Systemic absorption of an LHRH agonist and sex steroids following nasal spray administration. Pharm Res 11: S-425 (1995).
14. A. V. Schally, A. Arimura, Y. Baba, R. M. Nair H. Matsuo, T. W. Redding, and L. Debeljuk. Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun 43: 393-9 (1971).
15. U. B. Kompella, B. A. Dani. Metabolism of [Des-Gly10,D-Trp6]LHRH ethylamide in rabbit nasal tissue. Life Sci 58: 2201-7 (1996).
16. K. Koushik, G. Sunkara, P. Gwilt, and U. B. Kompella. Pathways and kinetics of deslorelin degradation in an airway epithelial cell line (Calu-1). Pharm Res 20: 779-87 (2003).
17. T. Kisseland, U. Werner Nasal delivery of peptides: an in vitro cell culture model for the investigation of transport and metabolism in human nasal epithelium. J Control Release 53: 195-203 (1998).
18. M. D. Donovan, G. L. Flynn, and G. L. Amidon. Absorption of polyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm Res 7: 863-8 (1990).
19. D. Cremaschi, C. Rossetti, M. T. Draghetti, C. Manzoni, and V. Aliverti. Active transport of polypeptides in rabbit nasal mucosa: possible role in the sampling of potential antigens. Pflugers Arch 419: 425-32 (1991).
20. D. Cremaschi, C. Porta, R. Ghirardelli, C. Manzoni, and I. Caremi. Endocytosis inhibitors abolish the active transport of polypeptides in the mucosa of the nasal upper concha of the rabbit. Biochim Biophys Acta 1280: 27-33 (1996).
21. K. N. Koushik, U. B. Kompella. Transport of deslorelin, an LHRH agonist, is vectorial and exhibits regional variation in excised bovine nasal tissue. J Pharm Pharmacol 56: 861-8 (2004).
22. Y. W. Chien, S. F. Chang. Intranasal drug delivery for systemic medications. Crit Rev Ther Drug Carrier Syst 4: 67-194 (1987
23. H. Critchley, S. S. Davis, N. F. Farraj, and L. Illum. Nasal absorption of desmopressin in rats and sheep. Effect of a bioadhesive microsphere delivery system. J Pharm Pharmacol 46: 651-6 (1994).
24. K. Koushik, N. Bandi, S. Sundaram, and U. B. Kompella. Evidence for LHRH-receptor expression in human airway epithelial (Calu-3) cells and its role in the transport of an LHRH agonist. Pharm Res 21: 1034-46 (2004).
25. A. Adjei, D. Sundberg, J. Miller, and A. Chun. Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm Res 9: 244-9 (1992).
26. P. R. Byronand, J. S. Patton. Drug delivery via the respiratory tract. J Aerosol Med 7: 49-75 (1994).
27. J. S. Patton. Pulmonary delivery of drugs for bone disorders. Adv Drug Deliv Rev 42: 239-48 (2000).
28. K. Koushik, U. B. Kompella. Particle and device engineering for inhalation drug delivery. Drug Del Technol 4: 40-50 (2004).
29. D. A. Groneberg, C. Witt, U. Wagner K. F. Chung, and A. Fischer. Fundamentals of pulmonary drug delivery. Respir Med 97: 382-7 (2003).
30. H. Berger N. Heinrich, E. Albrecht, U. Kertscher, J. Oehlke, M. Bienert, H. Schafer, I. Baeger and B. Mehlis. Gonadotropin-releasing hormone (GnRH) analogs: relationship between their structure, proteolytic inactivation and pharmacokinetics in rats. Regul Pept 33: 299-311 (1991).
31. K. Han, J. S. Park, Y. B. Chung, M J. Lee, D. C. Moon, and J. R. Robinson. Identification of enzymatic degradation products of luteinizing hormone releasing hormone (LHRH)/[D-Ala6] LHRH in rabbit mucosal homogenates. Pharm Res 12: 1539-44 (1995).
32. M. E. Brewster J. W. Simpkins, M. S. Hora, W. C. Stern, and N. Bodor. The potential use of cyclodextrins in parenteral formulations. J Parenter Sci Technol 43: 231-40 (1989).
33. Y. Ozkan, T. Atay, N. Dikmen, A. Isimer, and H. Y. Aboul-Enein. Improvement of water solubility and in vitro dissolution rate of gliclazide by complexation with beta-cyclodextrin. Pharm Acta Helv 74: 365-70 (2000).
34. M. Yamamoto, F. Hirayama, and K. Uekama. Improvement of stability and dissolution of prostaglandin E1 by maltosyl-beta-cyclodextrin in lyophilized formulation. Chem Pharm Bull (Tokyo) 40: 747-51 (1992).
35. F. W. Merkus, J. C. Verhoef E. Marttin, S. G. Romeijn, P. H. van der Kuy, W. A. Hermens, and N. G. Schipper. Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev 36: 41-57 (1999).
36. K. N. Koushik, N. Bandi, and U. B. Kompella. Interaction of [D-Trp6, Des-Gly10] LHRH ethylamide and hydroxy propyl beta-cyclodextrin (HPbetaCD): thermodynamics of interaction and protection from degradation by alpha-chymotrypsin. Pharm Dev Technol 6: 595-606 (2001).
37. K. Koushik, D. S. Dhanda, N. P. Cheruvu, and U. B. Kompella. Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes. Pharm Res 21: 1119-26 (2004).
38. K. J. Kimand, A. B. Malik. Protein transport across the lung epithelial barrier. Am J Physiol Lung Cell Mol Physiol 284: L247-59 (2003).
39. K. J. Kim, Y. Matsukawa, H. Yamahara, V. K. Kaira, V. H. Lee, and E. D. Crandall. Absorption of intact albumin across rat alveolar epithelial cell monolayers. Am J Physiol Lung Cell Mol Physiol 284: L458-65 (2003).
40. S. S. Kakar L. Jennes. Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues. Cancer Lett 98: 57-62 (1995).
41. A. Cornea, J. A. Janovick, X. Lin, and P. M. Conn. Simultaneous and independent visualization of the gonadotropin-releasing hormone receptor and its ligand: evidence for independent processing and recycling in living cells. Endocrinology 140: 4272-80 (1999).
42. J. G. Hardy, T. S. Chadwick. Sustained release drug delivery to the lungs: an option for the future. Clin Pharmacokinet 39: 1-4 (2000).
43. J. D. Brain. Macrophages in the respiratory tract. In A. P. Fishman, and Fisher, A.B. (ed), Handbook of physiology: the respiratory system 1. (A. P. Fishman, and Fisher, A.B., ed), American Physiological Society, Bethesda (MD), 1985, pp. 447-471.
44. M. R. Bailey, F. A. Fry, and A. C. James. The long-term clearance kinetics of insoluble particles from the human lung. Ann Occup Hyg 26: 273-90 (1982).
45. M. Geiser. Morphological aspects of particle uptake by lung phagocytes. Microsc Res Tech 57: 512-22 (2002).
46. H. Ayhan, A. Tuncel, N. Bor, and E. Piskin. Phagocytosis of monosize polystyrene-based microspheres having different size and surface properties. J Biomater Sci Polym Ed 7: 329-342 (1995).
47. Y. a. I. Tabata, Y. Phagocytosis of polymer microspheres. Advances in Polymer Science 94: 107-141 (1990).
48. D. A. Edwards, J. Hanes, G. Caponetti, J. Hrkach, A. Ben-Jebria, M. L. Eskew, J. Mintzes, D. Deaver, N. Lotan, and R. Langer. Large porous particles for pulmonary drug delivery. Science 276: 1868-71 (1997).
49. D. A. Edwards, A. Ben-Jebria, and R. Langer. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 85: 379-85 (1998).
50. A. Ben-Jebria, D. Chen, M. L. Eskew, R. Vanbever, R. Longer, and D. A. Edwards. Large porous particles for sustained protection from carbachol-induced bronchoconstriction in guinea pigs. Pharm Res 16: 555-61 (1999).
51. D. A. Edwards, C. Dunbar. Bioengineering of therapeutic aerosols. Annu Rev Biomed Eng 4: 93-107 (2002).
52. P. Giunchedi, B. Conti, I. Genta, U. Conte, and G. Puglisi. Emulsion spray-drying for the preparation of albumin-loaded PLGA microspheres. Drug Dev Ind Pharm 27: 745-50 (2001).
53. J. Fiegel, C. Ehrhardt, U. F. Schaefer C. M. Leh, and J. Hanes. Large porous particle impingement on lung epithelial cell monolayers - toward improved particle characterization in the lung. Pharm Res 20: 788-96 (2003).
54. L. A. Dellamary, T. E. Tarara, D. J. Smith, C. H. Woelk, A. Adractas, M. L. Costello, H. Gill, and J. G. Weers. Hollow porous particles in metered dose inhalers. Pharm Res 17: 168-74 (2000).
55. A. I. Bot, T. E. Tarara, D. J. Smith, S. R. Bot, C. M. Woods, and J. G. Weers. Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract. Pharm Res 17: 275-83 (2000).
56. K. Koushik, U. B. Kompella. Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process. Pharm Res 21: 524-35 (2004).
57. J. Wang, A. Ben-Jebria, and D. A. Edwards. Inhalation of estradiol for sustained systemic delivery. J Aerosol Med 12: 27-36 (1999).